Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine proposal contains "inadequate" small business impact analysis -- SBA.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRINE PROPOSED RULE IMPACT ON SMALL BUSINESSES NEEDS FURTHER ANALYSIS via FDA outreach efforts, the Small Business Administration Office of Chief Counsel for Advocacy states in Feb. 3 comments on FDA's proposed regulation of ephedrine alkaloid-containing dietary supplements. "FDA has done an inadequate job of analyzing the impact of the regulation on small entities and in identifying and analyzing less burdensome alternatives," SBA maintains, adding the agency "should develop an outreach strategy to obtain more reliable industry data." The proposal was published in June ("The Tan Sheet" June 9, 1997, pp. 20-23).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088080

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel